Back HIV/AIDS

HIV / AIDS

EACS 2017: Boosted Protease Inhibitor + Lamivudine Effective for HIV Maintenance Treatment

HIV maintenance treatment with 2 drugs, a boosted protease inhibitor and lamivudine, is just as effective as 3-drug treatment with a boosted protease inhibitor for people who already have fully suppressed viral load, according to a meta-analysis of clinical trials presented last weekat the 16th European AIDS Conference (EACS 2017) in Milan.

alt

EACS 2017: ABX464 Reduces HIV Reservoir But Does Not Delay Vial Rebound

ABX464, a new drug that stimulates the clearance of HIV from infected cells, reduces the reservoir of HIV DNA in the body but does not delay the rebound of viral load when antiretroviral treatment is interrupted, Linos Vandekerckhove of the University of Ghent reported at the 16th European AIDS Conference (EACS 2017) last week in Milan.

alt

IDWeek 2017: Single-Tablet Protease Inhibitor Regimen Maintains Viral Suppression for a Year

People who switched from a multi-pill antiretroviral regimen to the first 1-pill, once-daily regimen that includes a protease inhibitor maintained undetectable viral load for a year, according to a report at the IDWeek 2017 conference last week in San Diego.

alt

IAS 2017: Why Curing Cancer May Be Like Curing HIV -- and May Be As Difficult

For the last few years, a specialist symposium on HIV cure research has preceded the annual International AIDS Society meetings, and this year was no exception, with a 2-day forum at the Curie Institute in Paris before the opening of the 9th IAS Conference on HIV Science (IAS 2017).

alt

Virally Suppressed People Have "Effectively No Risk" of Transmitting HIV, Says CDC

The US Centers for Disease Control and Prevention (CDC) announced on September 27, National Gay Men’s HIV/AIDS Awareness Day, that HIV diagnoses had fallen among white gay and bisexual men and remained stable among African-American gay men between 2010 and 2014, its last complete year of figures.

alt

IDWeek 2017: Long-Acting Monoclonal Antibody Effective Against Multidrug-Resistant HIV

Ibalizumab, a long-acting monoclonal antibody that prevents HIV from entering cells, maintained viral suppression for a year in people with highly resistant HIV and limited treatment options, according to a presentation at the IDWeek 2017 conference last week in San Diego.

alt

IAS 2017: Cancer Research May Offer Clues for HIV Cure Research -- and Vice Versa

There is a growing overlap between the fields of cancer and HIV cure research, and approaches that help fight one disease may offer clues about the other. This convergence was the theme of the HIV Cure and Cancer Forum preceding the International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris -- the first time cancer has joined the HIV cure agenda.

alt